Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 8/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282481 | 0.85 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2ABL1SCD | |
| SCHEMBL221631 | 0.85 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2GSK3BABL1 | |
| SCHEMBL220913 | 0.85 | GSK3B (0.40) | NPC1RAB9ASMN1; SMN2GSK3BABL1 | |
| SCHEMBL2739674 | 0.83 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2GSK3BABL1 | |
| SCHEMBL1282762 | 0.83 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2GSK3BABL1 | |
| SCHEMBL222305 | 0.81 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ABL1SCD | |
| SCHEMBL1684084 | 0.81 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2ABL1SCD | |
| SCHEMBL18365219 | 0.80 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2ABL1SCD | |
| SCHEMBL222097 | 0.79 | — | — | |
| SCHEMBL1684082 | 0.79 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2ABL1SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8389516-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8389516-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8389516-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2034997-B1 | ANTIBACTERIAL COMPOSITIONS | BIOTA EUROPE LTD (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| EP-2034997-A1 | ANTIBACTERIAL COMPOSITIONS | Prolysis Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007148093-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD. (GB) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004221-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | NPC1 2581/4885RAB9A 3590/4885SMN1; SMN2 3141/4885 |
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | NPC1 3471/4885RAB9A 3588/4885SMN1; SMN2 3693/4885 |
| US-20110263590-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | NPC1 2378/4885RAB9A 3558/4885SMN1; SMN2 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.